Vaxcyte Narrows Timing Of Topline Data From VAX-31 Adult Phase 3 OPUS-1 Trial To End Of October 2026 From Q4 2026
Share
Why It Matters
Vaxcyte said it will share results from an important vaccine test a bit earlier than planned—by the end of October instead of sometime in the last three months of 2026. When a company narrows down when it will share results, watch to see if the news ends up being good or disappointing.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.